Sun Pharmaceutical Industries Ltd

Sun Pharmaceutical Industries Ltd is up for a third straight session today. The stock is quoting at Rs 1638.8, up 1.15% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.19% on the day, quoting at 25378.1. The Sensex is at 82867.93, up 0.21%. Sun Pharmaceutical Industries Ltd has gained around 0.75% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has gained around 1.43% in last one month and is currently quoting at 22241.35, up 0.63% on the day. The volume in the stock stood at 11.32 lakh shares today, compared to the daily average of 26.7 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 1643.3, up 1.08% on the day. Sun Pharmaceutical Industries Ltd is down 11.23% in last one year as compared to a 0.15% slide in NIFTY and a 2.39% slide in the Nifty Pharma index.The PE of the stock is 78.05 based on TTM earnings ending June 25.Powered by Capital Market - Live

Sun Pharmaceutical Industries Ltd is up for a third straight session today. The stock is quoting at Rs 1612.3, up 1.19% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.1% on the day, quoting at 24997.1. The Sensex is at 81530.73, up 0.13%. Sun Pharmaceutical Industries Ltd has slipped around 0.61% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has slipped around 2.11% in last one month and is currently quoting at 22122.05, up 0.41% on the day. The volume in the stock stood at 8.99 lakh shares today, compared to the daily average of 27.31 lakh shares in last one month. The benchmark September futures contract for the stock is quoting at Rs 1616.7, up 1.09% on the day. Sun Pharmaceutical Industries Ltd is down 13.57% in last one year as compared to a 1.54% slide in NIFTY and a 5.19% slide in the Nifty Pharma index.The PE of the stock is 76.77 based on TTM earnings ending June 25.Powered by Capital Market - Live

The classification follows an inspection conducted by the FDA from June 2 to June 13, 2025, during which eight observations related to current good manufacturing practices (CGMP) were issued. Sun Pharma stated that the Halol site remains under an import alert, restricting shipments to the United States, except for certain products exempted due to drug shortages. The restrictions will continue until the facility meets the FDA's CGMP compliance requirements. The company added that it remains committed to working closely with the FDA and addressing all observations to bring the facility into full compliance. Sun Pharmaceutical Industries is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. The company's consolidated net profit tumbled 19.64% to Rs 2,278.63 crore despite of 10.07% increase in revenue from operations to Rs 13,786.07 crore in Q1 FY26 over Q1 FY25. The drop in profit was primarily due to a one-time exceptional charge of Rs 818 crore during the quarter. Shares of Sun Pharmaceutical Industries shed 0.33% to Rs 1,589.80 on the BSE. Powered by Capital Market - Live

The broker cited stretched valuations and slower-than-expected traction in speciality drugs. It flagged concerns around psoriasis drug Ilumya's heavy Medicare exposure, potential pricing pressures, and limited earnings visibility despite strong initial uptake. It warned that a 10% price cut in Ilumya could erode Sun Pharma's EPS by 4%. Sun Pharmaceutical Industries is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets. The company's consolidated net profit tumbled 19.64% to Rs 2,278.63 crore despite of 10.07% increase in revenue from operations to Rs 13,786.07 crore in Q1 FY26 over Q1 FY25. The drop in profit was primarily due to a one-time exceptional charge of Rs 818 crore during the quarter. Powered by Capital Market - Live

Sun Pharmaceutical Industries Ltd gained for a third straight session today. The stock is quoting at Rs 1640.3, up 1.12% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.56% on the day, quoting at 24624.55. The Sensex is at 80559.71, up 0.4%. Sun Pharmaceutical Industries Ltd has slipped around 2.51% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has slipped around 1.12% in last one month and is currently quoting at 21753.5, up 1.87% on the day. The volume in the stock stood at 5.36 lakh shares today, compared to the daily average of 21.96 lakh shares in last one month. The benchmark August futures contract for the stock is quoting at Rs 1642.4, up 1.12% on the day. Sun Pharmaceutical Industries Ltd is down 5.82% in last one year as compared to a 1.99% spurt in NIFTY and a 0.67% spurt in the Nifty Pharma index.The PE of the stock is 78.13 based on TTM earnings ending June 25.Powered by Capital Market - Live

The drop in profit was primarily due to a one-time exceptional charge of Rs 818 crore during the quarter. Profit before exceptional items and tax stood at Rs 3,990.8 crore in Q1 FY26, up 16.6% YoY. In Q1 FY26, EBITDA stood at Rs 4,301.7 crore (including other operating revenues), up 19.2%, with resulting EBITDA margin of 31.1%. India formulations sales were Rs 4,721.1 crore for Q1 FY26, a growth of 13.9% over Q1 FY25 and accounted for 34.2% of total consolidated sales for the quarter. US formulation sales were $473 million for Q1 FY26, up 13.9% over Q1 FY25 and accounted for 29.3% of total consolidated sales for the quarter. Global Innovative Medicines (formerly the specialty business) sales were $311 million for Q1FY26, up 16.9% over Q1 last year and accounted for 19.3% of total consolidated sales for the quarter. Formulation sales in emerging markets were $298 million for Q1FY26, up by 5.1% and accounted for 18.5% of total consolidated sales. Formulation sales in Rest of World (RoW) markets were $219 million for Q1FY26, up by 15.5% and accounted for 13.6% of total consolidated sales for the quarter. In Q1 FY26, external sales of API were at Rs 540.4 crore, up by 9.3%. The company's API portfolio supports formulation business and API customers across geographies. Dilip Shanghvi, chairman and managing director, said, 'Sun had a strong performance during the quarter, where the overall growth reflects steady progress across all our markets. India continues to show strong momentum, contributing meaningfully to our performance. The U.S. launch of LEQSELVI represents an important step forward, offering a new treatment option for patients with severe alopecia areata. LEQSELVI augments our portfolio in dermatology and adds a growth engine to our Innovative Medicines business.' Sun Pharmaceutical Industries is the world's leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the US as well as Global Emerging Markets.Powered by Capital Market - Live

Net profit of Sun Pharmaceutical Industries declined 19.64% to Rs 2278.63 crore in the quarter ended June 2025 as against Rs 2835.62 crore during the previous quarter ended June 2024. Sales rose 10.07% to Rs 13786.07 crore in the quarter ended June 2025 as against Rs 12524.51 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales13786.0712524.51 10 OPM %31.2028.80 - PBDT4691.324078.63 15 PBT3990.773423.50 17 NP2278.632835.62 -20 Powered by Capital Market - Live

Sun Pharmaceutical Industries Ltd rose for a fifth straight session today. The stock is quoting at Rs 1713.4, up 0.66% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.07% on the day, quoting at 24697.95. The Sensex is at 80903.8, up 0.02%. Sun Pharmaceutical Industries Ltd has added around 2.25% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has added around 4.31% in last one month and is currently quoting at 22761.15, up 1% on the day. The volume in the stock stood at 5.9 lakh shares today, compared to the daily average of 17.79 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 1714, up 0.61% on the day. Sun Pharmaceutical Industries Ltd is up 0.69% in last one year as compared to a 0.64% fall in NIFTY and a 6.72% fall in the Nifty Pharma index.The PE of the stock is 95.56 based on TTM earnings ending March 25.Powered by Capital Market - Live

Sun Pharmaceutical Industries announced top-line results from two Phase 3 clinical studies evaluating the efficacy and safety of tildrakizumab 100 mg (ILUMYA') administered over 24 weeks for treatment of active psoriatic arthritis. Treatment with tildrakizumab 100 mg (ILUMYA) resulted in greater improvements in PsA signs and symptoms at Week 24 compared to treatment with placebo. Both the INSPIRE-1 and INSPIRE-2 studies achieved the primary endpoint, with a higher proportion of patients in the INSPIRE-1 and INSPIRE-2 studies treated with tildrakizumab achieving ACR20 responses at week 24, compared to those receiving placebo (p 0.05). We are excited to share that both the INSPIRE-1 and INSPIRE-2 clinical trials have successfully met their primary endpoints. These top-line results reinforce the therapeutic potential of ILUMYA as a treatment option for patients with active psoriatic arthritis. We extend our sincere gratitude to the patients, healthcare professionals and administrators whose contributions made the studies possible. We look forward to sharing the complete clinical data in the near future,' said Marek Honczarenko, MD, PhD, Senior Vice President and Head of Global Specialty Development at Sun Pharma.Powered by Capital Market - Live

The drug is indicated for the treatment of alopecia areata ' a condition in which the immune system attacks hair follicles, leading to hair loss on the scalp as well as other parts of the body. The pharmaceutical company announced LEQSELVI after entering into a settlement and license agreement with Incyte Corporation. Incyte had earlier accused Sun Pharma of patent infringement. Under the terms of agreement, the parties will seek dismissal of the pending LEQSELVI litigation in the United States District Court for the District of New Jersey and Sun and Incyte will mutually release each other of all claims that were raised or could have been raised in that litigation. As a part of agreement, Incyte has granted to Sun a limited, non-exclusive license to patents related to oral deuruxolitinib for certain agreed-upon non-hematology-oncology indications including alopecia areata, in the U.S. Sun will pay to Incyte an upfront amount, plus ongoing royalty payments until the expiry of the patents, in exchange for the settlement and license. The scrip had advnaced 2.71% to end at Rs 1727.70 on the BSE today. Powered by Capital Market - Live